Saga inks assay development deal with AstraZeneca

By staff writers

November 2, 2021 -- Swedish liquid biopsy and genomic testing provider Saga Diagnostics is developing new digital polymerase chain reaction (dPCR) assays for AstraZeneca.

Under the deal, Saga will create unique versions of its Sagasafe dPCR assays toward undisclosed methylated targets for analyses of tissue samples and liquid biopsies, according to the company. AstraZeneca will utilize the assays in a clinical research study.

Stilla launches Naica 6-color digital PCR system
Stilla Technologies has launched Naica, a digital polymerase chain reaction (PCR) system that features six fluorescent channels. Naica was introduced...
Thermo Fisher, AstraZeneca to develop NGS companion diagnostics
Thermo Fisher Scientific and AstraZeneca plan to co-develop companion diagnostics based on next-generation sequencing (NGS) to support targeted therapies.
Grail to collaborate with top companies for MRD detection
Cancer diagnostics startup Grail has announced collaborations with Amgen, AstraZeneca, and Bristol Myers Squibb to evaluate the ability of Grail's methylation-based...
Lynparza PARP approval opens door to more pancreatic cancer testing
Approval of the drug olaparib (Lynparza, Merck/AstraZeneca) by the U.S. Food and Drug Administration at the end of 2019 paves the way for more testing...

Copyright © 2021

Last Updated ls 11/2/2021 1:06:33 PM